Tags » Incyte

Lilly/Incite's New JAK Inhibitor, Barincitinib, Shows Promise

This week I got two exciting bits of news about barincitinib — a new JAK inhibitor developed by ELI Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY). 263 more words

Rheumatoid Arthritis

Eli Lilly, Incyte's rheumatoid arthritis drug studies show positive effect

Eli┬áLilly and Company and Incyte Corporation have announced on Wednesday that new data from RA-BEACON – a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) – showed baricitinib demonstrated significant improvement in patient-reported outcomes and health-related quality of life (HRQOL) measures, fatigue and pain compared with placebo. 482 more words